Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The NCI Annual Plan and Budget Proposal for Fiscal Year 2017 provides an overview of NCI’s priorities and key initiatives and the institute’s funding request.
-
The FDA has approved rolapitant to prevent chemotherapy-induced nausea and vomiting.
-
NCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium, which is intended to help to prioritize which agents to pursue in pediatric clinical trials.
-
Use of intraperitoneal chemotherapy, along with intravenous chemotherapy, improves survival in some women with advanced ovarian cancer, but its use in clinical practice has been limited, according to a new study.
-
The FDA has approved sonidegib for the treatment of patients with locally advanced basal cell carcinoma.
-
Survivors of childhood cancer have an elevated risk of developing second, distinct cancers into their forties and beyond, according to a new study.
-
Experts are convening for a conference on the dilemmas posed by overdiagnosis in many types of diseases. Overdiagnosis is generally defined as the diagnosis of a disease or condition that is unlikely to ever cause harm.
-
Women who are diagnosed with a condition called ductal carcinoma in situ generally have a low risk of dying from breast cancer, a new study has found.
-
The FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.
-
The FDA last month approved gefitinib (Iressa) for the treatment of some patients with lung cancer, marking the drug’s return to the U.S. market after an earlier withdrawal.